145 related articles for article (PubMed ID: 31706988)
1. CD5
Lu TX; Wu S; Zhou XY; Zhang Y; Hong TT; Cai DY; Hua HY; Qi XW; Wu XH
Exp Mol Pathol; 2020 Feb; 112():104326. PubMed ID: 31706988
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
3. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
5. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
Na HY; Choe JY; Shin SA; Kim HJ; Han JH; Kim HK; Oh SH; Kim JE
PLoS One; 2019; 14(10):e0224247. PubMed ID: 31644584
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of
Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
[TBL] [Abstract][Full Text] [Related]
10. Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.
Suzuki M; Muroi A; Nojima M; Numata A; Takasaki H; Sakai R; Yokose T; Miyagi Y; Koshikawa N
Proteomics Clin Appl; 2020 Jan; 14(1):e1900091. PubMed ID: 31721454
[TBL] [Abstract][Full Text] [Related]
11. Inferior survival in high-grade B-cell lymphoma with
McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
[TBL] [Abstract][Full Text] [Related]
12. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ennishi D; Takeuchi K; Yokoyama M; Asai H; Mishima Y; Terui Y; Takahashi S; Komatsu H; Ikeda K; Yamaguchi M; Suzuki R; Tanimoto M; Hatake K
Ann Oncol; 2008 Nov; 19(11):1921-6. PubMed ID: 18573805
[TBL] [Abstract][Full Text] [Related]
13. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
[No Abstract] [Full Text] [Related]
15. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
16. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
17. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
Richardson AI; Zhang D; Woodroof J; Cui W
Hum Pathol; 2019 Apr; 86():21-31. PubMed ID: 30496802
[TBL] [Abstract][Full Text] [Related]
18. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
20. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S
Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
